Viva Biotech Holdings (VB0) — Cash Flow-to-Debt Ratio
Viva Biotech Holdings (VB0) has a Cash Flow-to-Debt Ratio of 0.04x as of June 2023, meaning its operating cash flow of €158.72 Million could theoretically repay 0% of its total liabilities (€4.51 Billion) in one year. See VB0 cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Viva Biotech Holdings Cash Flow-to-Debt Ratio (2016–2024)
Historical debt coverage capacity for Viva Biotech Holdings across 9 annual periods. Also explore VB0 year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Viva Biotech Holdings (2016–2024)
Year-by-year debt coverage analysis for Viva Biotech Holdings. For market capitalisation and broader financial context, see market cap of Viva Biotech Holdings.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.12x | €373.99 Million | €3.23 Billion | ▲ +13.5% |
| 2023 | 0.10x | €383.40 Million | €3.76 Billion | ▲ +13.9% |
| 2022 | 0.09x | €386.05 Million | €4.32 Billion | ▲ +374.8% |
| 2021 | 0.02x | €77.83 Million | €4.13 Billion | ▲ +91.8% |
| 2020 | 0.01x | €43.18 Million | €4.40 Billion | ▼ -97.4% |
| 2019 | 0.38x | €46.01 Million | €121.39 Million | ▲ +769.8% |
| 2018 | 0.04x | €12.11 Million | €277.90 Million | ▼ -92.2% |
| 2017 | 0.56x | €27.89 Million | €49.64 Million | ▼ -32.6% |
| 2016 | 0.83x | €21.12 Million | €25.32 Million | — |